• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.63-81
• /
• 1994

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1996.04a
• /
• pp.229-230
• /
• 1996

The 116 annual meeting of the Pharmaceutical Society of Japan was held in Kanazawa from March 27 to 29 in 1996, Our presentation will be concerned to a few topics in this meeting. Recently not only pharmaco- and toxico-kinetic studies but also pharmaco- and toxico-dynamic studies are beginning to be worthy of notice. This is quite reasonable, because the blood concentration-time curves of a parent compound must be useful, but it is no more than a cross section for pharmaco- and toxico-dynamic in many organs and tissues as main reaction site for drug metabolism,

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1996.04a
• /
• pp.262-263
• /
• 1996

The 116 annual meeting of the pharmaceutical Society of Japan was held in Kanazawa from March 27 to 29 in 1996. Our presentation will be concerned to a few topics in this meeting. Recently not only pharmaco and toxico kinetic studies but also pharmaco and toxico dynamic studies are beginning to be worthy of notice. This is quite reasonable. because the blood concentration time curves of a parent compound must be useful, but it is no more than a cross section for pharmaco and toxico dynamics in many organs and tissues as main reaction site for drug metabolism.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.9 no.1
• /
• pp.17-21
• /
• 2023

In this study, we evaluated the targeting of prostate cancer (PCa) using [¹⁸F]Florastamin in non-clinical study, for the purpose of therapeutic monitoring of [¹⁷⁷Lu]Ludotadipep, a therapeutic radiopharmaceutical for PCa, [¹⁸F]Florastamin/[¹⁷⁷Lu]Ludotadipep was co-administered to a single-individual prostate tumor bearing mouse model, mimicking clinical condition. Considering the difference in half-life of the two isotopes (¹⁸F or ¹⁷⁷Lu), image scan of whole-body autoradiography was performed at 24 or 48 h after preparation of frozen section, respectively. Then, it was confirmed whether they showed the same targeting efficiency for the area of tumor. A tumor xenograft model was prepared using PSMA-overexpressing PC3-PIP prostate cancer cells. [¹⁸F]Florastamin [111 MBq (3 mCi) in 100 µL]/¹⁷⁷Lu]Ludotadipep [3.7 MBq (100 µCi) in 100 µL] was co-administered through the tail vein, and 2 hours after administration, the mice were frozen, and after freezing for 24 hours, whole-body cryosection was performed at 24 h after freezing. Image scanning using cryosection was performed after 24 or 48 hours after freezing, respectively. In the scan image after 24 hours, tumor uptake of [¹⁸F] Florastamin/[¹⁷⁷Lu]Ludotadipep were simultaneously observed specific uptake in the tumor. In the scan image after 48 hours in the same section, signal of ¹⁸F was lost by decay of radioisotope, and specific uptake image for [¹⁷⁷Lu]Ludotadipep was observed in the tumor. Uptake of [¹⁷⁷Lu]Ludotadipep was specific to the same tumor region where [¹⁸F]Florastamin/[¹⁷⁷Lu]Ludotadipep was uptake. These results suggested that [¹⁸F]Florastamin showed the same tumor uptake efficiency to PCa as [¹⁷⁷Lu]Ludotadipep, and effective therapeutic monitoring is expected to be enable using [¹⁸F]Florastamin during [¹⁷⁷Lu]Ludotadipep therapy for PCa.